Scholarlink

<p>Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase crucial for transcriptional elongation via phosphorylation of the C-terminal domain (CTD) of RNA polymerase II, thereby enabling productive mRNA synthesis. Given its pivotal role in gene expression, CDK9 represents a validated therapeutic target in cancer research. This study employed a sequential bioisosteric replacement strategy to identify novel CDK9 inhibitors. Initially, a library of 17,633 compounds was generated by replacing the core scaffold of 134 known inhibitors. Pharmacophore-based virtual screening reduced this set to 3,754 candidates, from which a highly predictive QSAR model identified compound 50224760_85 as the most promising lead. A second round of bioisosteric substitution yielded 66,966 novel structures, increasing chemical diversity and predicted bioactivity. QSAR analysis highlighted compounds 9550, 9724, and 31801 as representative molecules with favorable predicted properties and structural novelty. Density functional theory (DFT) calculations further revealed distinct electronic and chemical reactivity profiles across these top-ranked ligands. Molecular dynamics simulations demonstrated that all three ligands maintained enhanced stability within the ATP-binding pocket of CDK9 relative to the parent compound. Consistently, binding free energy and per-residue decomposition analyses confirmed robust interactions with catalytically relevant residues, supporting their potential as potential CDK9 inhibitors. Overall, this integrative strategy identified a rich dataset of CDK9-targeting ligands with predicted <i>K</i><sub><i>i</i></sub> values comparable to the most potent experimental compounds reported to date.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In silico-driven identification of potent CDK9 inhibitors through bioisosteric replacement and multi-stage virtual screening

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Juliana Amorim,
  • Luis Altamirano,
  • Denise Silva de Souza,
  • Chen Li,
  • Syeda Abida Ejaz,
  • Juan Carpio Arévalo

摘要

Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase crucial for transcriptional elongation via phosphorylation of the C-terminal domain (CTD) of RNA polymerase II, thereby enabling productive mRNA synthesis. Given its pivotal role in gene expression, CDK9 represents a validated therapeutic target in cancer research. This study employed a sequential bioisosteric replacement strategy to identify novel CDK9 inhibitors. Initially, a library of 17,633 compounds was generated by replacing the core scaffold of 134 known inhibitors. Pharmacophore-based virtual screening reduced this set to 3,754 candidates, from which a highly predictive QSAR model identified compound 50224760_85 as the most promising lead. A second round of bioisosteric substitution yielded 66,966 novel structures, increasing chemical diversity and predicted bioactivity. QSAR analysis highlighted compounds 9550, 9724, and 31801 as representative molecules with favorable predicted properties and structural novelty. Density functional theory (DFT) calculations further revealed distinct electronic and chemical reactivity profiles across these top-ranked ligands. Molecular dynamics simulations demonstrated that all three ligands maintained enhanced stability within the ATP-binding pocket of CDK9 relative to the parent compound. Consistently, binding free energy and per-residue decomposition analyses confirmed robust interactions with catalytically relevant residues, supporting their potential as potential CDK9 inhibitors. Overall, this integrative strategy identified a rich dataset of CDK9-targeting ligands with predicted Ki values comparable to the most potent experimental compounds reported to date.